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On February 3, 2010, a “Letter of Concern from Bioethicists,” organized by fetaldex.org was sent to 
report suspected violations of the ethics of human subjects research in the off-label use of 
dexamethasone during pregnancy by Dr. Maria New. Copies of this letter were submitted to the FDA 
Office of Pediatric Therapeutics, the Department of Health and Human Services (DHHS) Office for 
Human Research Protections, and three universities where Dr. New has held or holds appointments. We 
provide a critical appraisal of the Letter of Concern and show that it makes false claims, misrepresents 
scientific publications and websites, fails to meet standards of evidence-based reasoning, makes 
undocumented claims, treats as settled matters what are, instead, ongoing controversies, offers “mere 
opinion” as a substitute for argument, and makes contradictory claims. The Letter of Concern is a case 
study in unethical transgressive bioethics. We call on fetaldex.org to withdraw the letter and for co-
signatories to withdraw their approval of it. 
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On February 3, 2010, a “Letter of Concern from Bioethicists” was sent to report 
suspected violations of the ethics of human subjects research in the off-label use (i.e., 
not for purposes approved by FDA) of dexamethasone (a glucocorticoid steroid) 
during pregnancy “for the purposes [sic] of preventing genital virilization associated 
with CAH[congenital adrenal hyperplasia] in 46,XX females,” by Dr. Maria New, 
Professor of Pediatrics at Mount SinaiMedical Center in New York City (fetaldex.org 
2010a; Appendix). The effort was organized by fetaldex.org, which continues to 
update this “action:” “We have organized a group of professional researchers in 
bioethics and allied fields to file formal letters of concern” (fetaldex.org 2010b). 
Copies of this letter were submitted to the U.S. Food and Drug Administration (FDA) 
Office of Pediatric Therapeutics, the U.S. Department of Health and Human Services 
(DHHS) Office for Human Research Protections, Mount Sinai Medical Center, Weill 
Medical College of Cornell University (“from which much of this treatment appears to 
have been administered, under Dr. New’s guidance” when she served on Cornell’s 
faculty), and Florida International University (“where Dr. New is Associate Dean for 
Clinical Research”). 
 
The stated purpose of fetaldex.org, which was founded in 2010, is the 
following:  
 
This website seeks to raise awareness regarding the 
prenatal use of dexamethasone, a Class Csteroid, to 
attempt to prevent a female fetus from developing genitals 
that are more in-between a male and female type. 
(fetaldex.org 2010b) 
 
Ellen Feder, Ph.D., of American University, appears as corresponding author, 
followed by 31 co-signatories and three “additional supporters of inquiry (offered to 
sign after letters had already gone in).” 
 
The “Letter of Concern from Bioethicists” (hereinafter referred to as LoC) and 
the subsequent activities of fetaldex. org can usefully be characterized as an exampleof 
transgressive bioethics. Transgressive bioethics combines attention-getting tropes with 
traditional philosophical argument to challenge accepted clinical practice or research 
in a deliberately provocative fashion, to expose what is taken to be unethical practice 
and reform it. Transgressive bioethics can be understood as aiming to fulfill a 
traditional role of the humanities: to speak truth to power in a conspicuous fashion, to 
bring power to account. There is nothing intrinsically objectionable to transgressive 
bioethics, when it meets the intellectual and moral standards required to produce a 
public discourse of bioethics that is “reasonable” (Jonsen 1998, 353). The purpose of 
this paper is to show that the “Letter of Concern from Bioethicists” and the subsequent 
activities of fetaldex.org fail to meet these intellectual and moral standards, making 
this episode a case study in unethical transgressive bioethics. 
 
DR. NEW’S RESEARCH 
 
The target of the LoC is the research of Dr. New. The first requirement of 
sound bioethics, including transgressive bioethics, is reproducing empirically 
verifiable facts completely and accurately (De Grazia and Beauchamp 2001). We 
therefore start with an account of Dr. New’s research on prenatal use of 
dexamethasone to prevent virilization of the female fetus affected by congenital 
adrenal hyperplasia (CAH). CAH is a genetic hormonal disorder resulting in anatomic 
and physiologic masculinization of females. 
 
Dr. New is one of the leading pediatric endocrinologists in the world, having 
made many contributions to our understanding and treatment of adrenal disorders. 
Many scholars have written about the most frequent adrenal disorder, i.e., CAH owing 
to 21-hydroxylase deficiency (21OHD). Indeed, the first anatomical description was 
reported De Chrecchio (1865) in Italy. Grunberger and Boschitsch (1981) reported the 
case histories of 22 adult female patients aged 15 to 27 years before any prenatal 
therapeutic program had been developed. All treatment was at that time postnatal. 
Because of genital masculinization and, in the majority of cases, despite some form of 
corrective genital surgery (mostly clitorectomy), 11 of the women could not engage in 
heterosexual intercourse. Menarche occurred spontaneously in only 10 cases. Because 
prenatal testing was not yet available, the diagnosis was made postpartum, at which 
time the treatment of choice was the administration of a corticosteroid. From the 
standpoint of ameliorating genital ambiguity (but one conspicuous effect of high levels 
of intrauterine androgen exposure), intervention at this stage is considerably less than 
efficacious. 
 
With the advent of prenatal diagnosis of CAH through chorionic villus 
sampling or amniocentesis (depending on when the pregnant woman first presents for 
obstetric care) came the opportunity for earlier therapeutic intervention in pregnant 
women at high risk for carrying a child with CAH. The pioneer in prenatal treatment 
to prevent genital ambiguity was Maguelone Forest in Lyon, France, who reported the 
first prenatal treatment of CAH in 1987 (Forest, B´etuel, and David 1987). In 1986 Dr. 
New utilized Dr. Forest’s protocol to initiate prenatal diagnosis and treatment in the 
United States (New 1990; Karaviti et al. 1992). Many other countries have now begun 
a program of prenatal diagnosis and treatment of CAH to prevent genital ambiguity. 
The protocol is as follows. 
 
An obstetrician who performs chorionic villus sampling or amniocentesis 
requests prenatal diagnosis by sending a sample of tissue to Dr. New. The pregnant 
woman’s obstetrician makes a referral to Dr. New for the purpose of tissue analysis for 
21OHD. DNA is sent to Dr. New’s laboratory for analysis. She often requires DNA 
from the father as well, unless it was obtained from a previous pregnancy consultation. 
 
The pregnant woman has requested prenatal diagnosis and treatment because 
she has a member of her family who is affected with 21OHD and therefore the fetus is 
at risk. Prenatal treatment with dexamethasone for 21OHD must be initiated before the 
9th week of gestation to be effective, because sexual differentiation of genitalia 
typically occurs between the 9th and 13th week of gestation and chorionic villus 
sampling or amniocentesis cannot safely be performed prior to this milestone. Once 
the presence of normal 21OHD is identified and/or the fetus is identified as male, 
dexamethasone therapy is discontinued. Male fetuses and unaffected female fetuses do 
not require prenatal treatment, but neither the referring physician nor Dr. New knows 
this until the genetic diagnosis is made. Therefore, treatment is initiated by the 
referring obstetrician blind until the status of the fetus is determined (male or female, 
affected or unaffected). 
 
DNA diagnosis takes about 2–3 weeks, depending on whether the cells grow 
well enough. The dose of dexamethasone is 20 µg per kilogram per day in three 
divided doses, based on prepregnancy weight, with a maximum dose of 1.5 mg of 
dexamethasone per day. When the genetic information becomes available, Dr. New’s 
office immediately calls the referring obstetrician to report whether the fetus is a male 
or unaffected female and advises the doctor to stop the treatment. If it is a female that 
is affected genetically, the woman is administered dexamethasone until term. Dr. New 
asks for a postnatal follow-up to be sure that the prenatal diagnosis is correct. Follow-
up data are gathered by Dr. New under an institutional review board (IRB)-approved 
protocol with informed consent for data collection, analysis, and reporting (Trautman 
et al. 1995; New et al. 2001). 
 
The short-term outcome of preventing genital ambiguity in the affected female 
is 100% effective, providing that the pregnant woman is compliant and the 
dexamethasone is administered properly. The referring obstetrician obtains consent 
and writes the prescription for dexamethasone. Frequently, Dr. New must provide 
advice as to the dose and the duration. It is of note that Dr New herself has written the 
prescription for dexamethasone for only one patient: a pregnant woman who is herself 
a patient with a severe form of CAH who became pregnant with a female fetus who 
was also affected with a severe form of CAH (personal communication with Dr. New). 
 
Dexamethasone is administered at a very low dose (20 µg/kg/day of 
prepregnancy weight in 3 divided doses). At this low dose, dexamethasone does not 
have teratogenic potential, and furthermore, because the therapy does not begin until 
just before the ninth week of gestation, organogenesis of the major organs has been 
completed, so on both counts a risk for induced birth defects is not present. 
 
To date more than 800 fetuses have been diagnosed by genetic analysis of fetal 
tissue worldwide, so that in many countries, including the United States, prenatal 
diagnosis and treatment has become the standard of medical care. It should also be 
pointed out that the regulatory agencies in some countries have approved this protocol. 
This status of prenatal use of dexamethasone as standard of care is reflected in the 
major obstetrics textbooks. Danforth’s Obstetrics is illustrative: 
 
Approximately 90% of patients with CAH during 
pregnancy have a partial or complete deficiency of the 
21-hydroxylase enzyme. The resultant decrease in 
cortisol production leads to increased ACTH stimulation, 
which then results in both increased production of 
androgenic cortisol precursors . . . and decreased 
production of aldosterone. Because these androgenic 
steroids readily cross the placenta, pregnancies 
complicated by significant maternal 21-hydroxylase 
deficiency are at increased risk for fetal virilization. 
Such virilization is most apparent in female infants, 
although male infants also may have somewhat enlarged 
external genitalia. The risk of fetal virilization is reduced 
if pregnant patients with CAH receive adequate basal 
glucocorticoid replacement together with additional 
glucocorticoid in times of stress. Mineralocorticoid 
replacement should be continued as well. (Krakow 2008) 
 
DR. NEW HAS “LONG PRESCRIBED” PRENATAL EXAMETHASONE:A 
FALSE CLAIM  
 The LoC states in its second paragraph: 
 
It is our understanding that Dr. New has long prescribed 
dexamethasone for purposes of preventing genital 
virilization associated with CAH in 46,XX females. 
 
Dr. New has prescribed dexamethasone prenatally in only one case, as we 
documented earlier. This central factual claim of the LoC is therefore false. That it 
could be advanced reflects the failure to undertake the research required to document 
this claim. Had such research been undertaken, the claim could not have been 
truthfully made. Making false claims as a consequence of the failure to meet the 
standard of reproducing empirically verifiable facts completely and accurately (De 
Grazia and Beauchamp 2001) is intellectually irresponsible and therefore unethical 
transgressive bioethics. By itself, this false claim discredits the LoC. However, there 
are multiple additional flaws in it that betray its systematically unethical nature. We 
address each in turn. 
 
PRENATAL ADMINISTRATION FOR DEXAMETHASONE IS COSMETIC: 
FALSE REPRESENTATION OF THE POSITION OF A SCIENTIST 
 
The second paragraph of LoC states:  
 
Genital virilization is a cosmetic issue, one that has been 
recognized within Dr. New’s field as independent of the 
genuine medical concerns—often serious and life-
threatening in some forms of CAH—unaddressed by 
prenatal dexamethasone treatment. That is to say, prenatal 
treatment with dexamethasone is intended to avoid a 
cosmetic issue associated with CAH, rather than to treat 
the medical issues that should be the primary concern of 
physicians. (emphasis original) 
 
No argument is made to support the clinical ethical judgment that genital 
virilization of females is a “cosmetic issue.” Instead, reference is made to a paper by 
Walter Miller (1999), a pediatric endocrinologist. 
 
Miller reports the complications of virilization as “persistence of a urogenital 
sinus, labioscrotal fusion and clitoromegaly, which are surgically correctable. This 
fetal hyperandrogenism may alsomasculinize the brains of affected females” (Miller 
1999, 537). The LoC mentions only one of these complications, clitoromegaly, 
without explanation. 
 
Miller reports on the use of prenatal dexamethasone, “There is now sufficient 
clinical experience so that present dexamethasone protocols result in little or no 
masculinization of the female genitalia” (Miller 1999, 537), and cites work by Dr. 
New in support. Miller goes on to make the case that prenatal use of amethasone is 
“experimental.” He points out that unaffected fetuses “will receive at least 6 weeks of 
dexamethasone treatment before a diagnosis is made” (Miller 1999, 537); that “only 1 
in 8 pregnancies to a couple with a previously affected child has a theoretical chance 
to be helped by prenatal therapy” (Miller 1999, 538); that the dosages exceed normal 
fetal glucocorticoid levels by a factor of 10; that the mechanism by which virilization 
may be altered is not well understood; and that “the teratogenic effect of 
dexamethasone has not been evaluated definitively” (Miller 1999, 538).Miller 
emphasizes the point that the long-term risks are not well understood as “most 
difficult” (Miller 1999, 538). He concludes: 
 
The genitalia of virilized females can be repaired 
surgically but adrenogenization of the brain is irreversible; 
hence, prenatal dexamethasone treatment may offer unique 
advantages. However, the ethics of needlessly subjecting 7 
of 8 fetuses to an experimental therapy with unknown 
long-term consequences remain unresolved because the 
long-term safety and outcome have not been established. 
Therefore, prenatal treatment of CAH remains 
experimental. (Miller 199, 538) 
 
Miller goes on to call for the administration of prenatal dexamethasone under 
protocols limited to “large centers that receive a large enough number of patients to 
yield meaningful research results” (Miller 1999, 538–539). Miller also sets out the 
domains of information that should be included in the informed consent process for 
such research. 
 
Nowhere in his article does Miller use the word “cosmetic” or any of its 
cognates. The reference to the Miller paper in the LoC to support its claim that 
prenatal administration of dexamethasone is cosmetic is erroneous because it is 
inconsistent with the plain language of the Miller paper. Miller, as just quoted, 
characterizes virilized genitalia as surgically reparable but makes no mention that this 
is a cosmetic procedure. Instead, he treats such surgery as a medical issue “that should 
be of the primary concern of physicians,” to use the language of the LoC. Worse, 
Miller directly supports the opposite view when he acknowledges that virilization of 
the brain is an “irreversible” complication and thus of clinical significance. In 
summary, the LoC falsely represents Miller’s paper as stating that prenatal 
administration of dexamethasone is merely cosmetic. 
 
SUBSEQUENT ADMISSION THAT PRENATAL ADMINISTRATION 
OF DEXAMETHASONE IS NOT COSMETIC 
 
Hilde Lindemann, Ph.D., of Michigan State University, joined Drs. Feder and Dreger 
in a posting on the bioethics blog site of The Hastings Center, reiterating the claims 
advanced in the LoC (Lindemann, Feder, and Dreger 2010a). One response was from 
an interdisciplinary group from Harvard Medical School (Diamond et al. 2010). David 
Diamondand colleagues pointed out that virilization of females with CAH in its severe 
forms includes a persistent urogenital sinus, an anomaly in which the urethra and 
vagina form a single channel. They write: “Even without doing surgery on the 
enlarged clitoris, surgical reconstruction to separate the urinary and reproductive tracts 
in childhood is necessary to prevent urinary incontinence and infections leading to 
renal damage as well as to allow normal urination and future sexual function” 
(Diamond et al. 2010). Diamond and colleagues also point out that Miller 
underestimates the complications of neonatal surgery to correct this problem. 
Prevention of this anatomic anomaly, they correctly add, is not cosmetic. 
 
Drs. Lindemann, Feder, and Dreger responded as follows: 
 
The reason we did not pay enough attention to this point is 
explained by our focus on New’s work on prenatal 
dex[amethsasone], which appears after much review to 
stand out as atypical. In her promotion of prenatal dex to 
“at risk” women, New emphasizes the prevention of 
ambiguous genitalia as the most important aim of 
intervention. This has implied that ambiguous genitalia 
represent some kind ofmedical problem in and of 
themselves. 
 
Obviously it would be good if medically necessary 
interventions (for example, surgery to correct a severe 
urogenital sinus) could be made unnecessary through 
prevention, as some interventions for neural tube defects 
have been prevented through increasing fertile women’s 
intake of folic acid. That said, we remain extremely 
concerned about the way that prenatal dex is being 
promoted and administered, and we do not see the 
potential for a postnatal urogenital sinus as a license to do 
what has been done. (Lindemann, Feder, and Dreger 
2010b) 
 
This response amounts to an admission that the attenuation of virilization with 
dexamethasone prevents more than just clitoromegaly; it also prevents clinically 
significant anatomic anomalies and therefore prevents “medically necessary 
interventions,” not just cosmetic procedures. As a result, they contradict and thus 
nullify one of the central claims in the LoC, that prenatal administration of 
dexamethasone for affected female fetuses is merely cosmetic. 
 
MISREPRESENTATION OF CARES FOUNDATION WEBSITE 
 
The LoC cites a CARES (Congenital Adrenal Hyperplasia Research Education & 
Support) Foundation document twice. The website is described as “online promotion 
of the treatment of dexamethasone administered by Dr.New’s clinic.”  
 
The CARES Foundation was incorporated in 2001 as a 501(3)(c) nonprofit 
organization (CARES Foundation 2009). It is not associated with Dr. New’s clinic, as 
the LoC implies in its ambiguous wording. This website is also cited in the LoC to 
support its claim that Dr. New has recruited pregnant women “without the benefit of 
IRB oversight.” The website makes no such claim. The CARES website is thus 
misrepresented twice. 
 
PRENATAL ADMINISTRATION OF DEXAMETHASONE 
HAS SIGNIFICANT IATROGENIC RISK: FAILURE TO 
MEET THE STANDARDS OF EVIDENCE-BASED REASONING 
 
The LoC makes two related claims about the risk of prenatal administration of 
dexamethasone. The LoC concludes its second paragraph with: “Furthermore, use of 
prenatal dexamethasone has been demonstrated to bear significant iatrogenic risk.” 
The LoC concludes its fifth paragraph with: “contrary to the apparent claims aimed at 
prospective patients, dexamethasone treatment cannot responsibly be characterized as 
benign.”  
 
Claims about the clinical benefits and risks of any clinical intervention should 
be evidence based. Bioethics is held to this exacting intellectual standard no less than 
clinical practice and research (Sulmasy and Sugarman 2001). The accepted standard 
for establishing unacceptable risk of a clinical intervention is a systematic review of 
the literature. No such review is described in the LoC. Instead, five papers are cited 
and no search strategy is described, in a letter being sent to federal agencies committed 
to evidence-based advancement of biomedical science and clinical practice. The LoC 
has an intellectual obligation to rebut Dr. New’s work by appealing to an evidence-
based analysis of her work in the context of the results of a systematic review. That 
theLoC fails to meet the fundamental standard of evidence-based reasoning is a 
fundamental error. 
 
The LoC asserts that perinatal treatment with dexamethasone puts fetuses at 
risk for neurotoxicity. The LoC references a study performed on 8 rhesusmonkeys (3 
of which were given placebo) thatwere administered dexamethasone in doses of 5 
mg/kg (Uno et al. 1994). For reference, the typical dose given to pregnant (human) 
women was 20 µg/kg. The LoC provides no justification for its extrapolation from the 
results of a study of 5 rhesus monkeys that were administered a single, 200-fold higher 
dose of dexamethasone than that administered to human female fetuses affected by 
CAH. 
 
In support of its claim about “significant iatrogenic risk” the LoC cites a 2000 
NIH Consensus Development Conference Statement (National Institutes of Health 
Consensus Development Panel 2001). The LoC neglects to mention that this is a 
statement on the use of antenatal steroids to promote fetal maturation, a clinical entity 
very dissimilar fromCAH. The NIH statement does not address prenatal administration 
of dexamethasone to prevent the clinical complications of CAH. Prenatal use of 
steroids to promote fetal maturity occurs later in gestation and at a much higher dose. 
This fundamental clinical disanalogy to prenatal use of dexamethasone for prevention 
of virilization is not acknowledged, much less addressed in the LoC.  
 
Even if the NIH statement were clinically relevant, the statement does not 
support the claim of the LoC. This is because the LoC omits the conclusion of this 
statement, which reads: “The collective international data continue to support 
unequivocally the use and efficacy of a single course of antenatal corticosteroids using 
the dosage and interval of administration specified in the 1994 Consensus 
Development Conference report” (National Institutes of Health Consensus 
Development Panel 2001, 144, emphasis added). 
 
The fetaldex.org website refers to a summary (“Cognitive functions” 2009) 
that appeared in Growth, Genetics, and Hormones about a study to “show that this 
prenatal dex treatment may result in detrimental changes to the brains of children 
given the drug in the womb.” The “About the Journal” webpage for this publication 
(http://www.gghjournal.com/atAGlance.cfm, accessed April 22, 2010) does not 
describe this journal as peer reviewed. It is not listed in the Web of Knowledge journal 
citation reports and therefore has no impact factor. The fetaldex. org Web site does not 
report any of this information and does not report that it relies on a summary of an 
article cited in the LoC (Hirvikoski et al. 2007). 
 
The fetaldex.org website does not portray the summary accurately. It states that 
there was no statistically significant difference reported for such cognitive functions as 
verbal comprehension and IQ but that there were statistically significant differences 
for memory function. The accompanying “Editor’s Comment” to this study suggests 
several more problems: “the sample size is small limiting statistical power; the 
assessment of school performance was self-reported and based on a measure of limited 
utility in detecting subtle learning problems; the generalizability of the findings are 
limited to children younger than 18 years, i.e., the pattern of neurocognitive effects 
may depend on chronologic age” (Sandberg 2009). Furthermore, in the study in 
question, the control-group children in the study were CAH-unaffected. That is, this 
study did not actually have a control arm of patients not altered by dexamethasone 
therapy, so that the null hypothesis of the study fails to be invalidated by virtue of a 
key methodological flaw of the study. These crucial methodological limitations are left 
unmentioned on the fetaldex.org website and in the LoC. 
 
The LoC also cites a study (French et al. 2004) to support its claim that that 
prenatal administration of dexamethasone “results in detrimental changes to the brains 
of children.” The population studied was children whose mothers had been 
administered steroids for preterm births, not CAH-affected females. As in the case of 
its reference to the NIH Consensus Panel, analyzed earlier in this article, the LoC does 
not report this difference in populations, with the same disabling problems for the 
LoC. Worse, the paper reports a protective effect of fetal dexamethasone against 
cerebral palsy and an association with hyperactivity in children treated. These mixed 
results are not reported in the LoC and do not support its unequivocal claim about 
brain changes. 
 
Finally, the usual evidence-based approach to judging the efficacy of an 
intervention in a population is based on the number needed to treat (NNT) and the 
number needed to harm (NNH). The NNT for prenatal dexamethasone administration 
is 8 (the number of fetuses exposed before genetic analysis is completed and one 
affected fetus is identified). Contrast this to the NNT for childhood influenza 
vaccination to prevent one hospitalization per year: between 1031 and 3050 for 
children 6–23 months and between 4255 and 6897 for children 24–59 months of age 
(Lewis et al. 2007). The NNH for prenatal dexamethasone would have to be calculated 
on the basis of a systematic review of the literature that described statistically 
significant differences in harms between CAH-affected children who were prenatally 
treated with dexamethasone and CAH-affected children who were not. The peer-
reviewed papers cited in support of the LoC’s claim about “significant iatrogenic risk” 
are either human studies without the required control group or animal studies. 
Therefore, the NNH for prenatal dexamethasone for affected female fetuses cannot be 
calculated on the basis of the references in the LoC. The claim of the LoC that 
“prenatal dexamethasone has been demonstrated to bear significant iatrogenic risk” 
lacks empirical foundation and therefore violates the standards of evidence-based 
reasoning. 
 
Were the authors of the LoC more charitably attuned to the substance of Dr. 
New’s research, they would have found a number of studies over the years that 
examined, in great detail, concerns regarding neurotoxicity and all manner of other 
forms of potential teratogenicity. It turns out that Dr. New has pondered and studied 
the concerns regarding antenatal neurotoxicity in humans in publications going back to 
1995 (Trautman et al. 1995) and she continues to study the hypothesis today. In one 
2004 study (Meyer-Bahlberg et al. 2004), New and colleagues examined 174 children, 
newborn to age 12 years, who were exposed to dexamethasone perinatally, of which 
48 had CAH. These children were compared to 313 unexposed children, including 195 
with CAH. New and colleagues used four different developmental questionnaires 
chosen for age-appropriateness and found that exposure to dexamethasone 
demonstrated no statistically significant correlations between dexamethsone 
administration and developmental delay on any measure, in any of the groups. Dr. 
New has also authored studies demonstrating that dexamethasone-treated fetuses had 
no difference in birth weight, length, and head circumference and that the risk of fetal 
loss was not higher than the general population (New et al. 2001). Given the low 
prevalence of CAH, this is likely to be among the largest study populations ever 
available for this disease. 
 
By contrast, the PREDEX study relied upon by the LoC has been enrolling 
patients prospectively in several European countries since 1999, and had only reported 
enrolling 14 patients through 2004 (Lajic 2004). The lead investigator for PREDEX, 
Dr. Svetlana Lajic, has published several studies on the neurocognitive effects of 
perinatal administration of dexamethasone over several years (Lajic 2004; Hirvikoski 
2007; 2008). One study (Hirvikoski 2007) reported lower rates of verbal working 
memory and higher rates of social anxiety in CAH-unaffected patients treated with 
dexamethasone (n = 26), though this same index was measured and not identified as 
statistically significant by New and colleagues (n = 174). In a follow-up study, 
Hirvikoski and colleagues report that their previous findings were not able to be 
reproduced, and may have been the result of a Type I error due to small sample size 
(Hirvikoski, 2008), lending credence to the results of studying a larger sample size 
such as reported by New and colleagues. Regardless, the data cited by the authors of 
the LoC do not support the LoC’s claim that “dexamethasone treatment cannot 
responsibly be characterized as benign.” Indeed, the preponderance of evidence 
suggests that the therapy is benign. 
 
It is a perennial challenge to study the long-term effects of a therapy for a 
condition that has a low incidence and prevalence, particularly when the effects being 
studied (neurocognitive behaviors) are affected by a vast array of factors. It is 
therefore all the more impressive that a dispassionate review of the empirical literature 
on the subject finds that Dr. New’s work represents the most methodologically sound 
and statistically convincing evidence that significant adverse neurocognitive outcomes 
attributable to perinatal dexamethasone therapy have yet to be convincingly reported. 
Assertions to the contrary have no basis in the empirical literature on the subject. 
 
OFF-LABEL ADMINISTRATION OF DEXAMETHASONE IS RESEARCH 
THAT SHOULD BE CONDUCTED ONLY WITH IRB OVERSIGHT: AN 
APPEAL TO A NONEXISTENT ETHICAL STANDARD 
 
The third paragraph of the LoC states:  
 
Off-label use of prescription medication is a long-time 
practice of medicine that has not been understood to 
constitute research requiring IRB oversight. We do not 
take issue here with the practice of off-label prescribing in 
general. We are concerned instead with a particular 
instance of what appears to constitute a de facto clinical 
trial involving many hundreds of patients now among the 
targeted “subjects” of long-term research. In clear 
violation of established bioethical protocols, these 
pregnant women appear to have been recruited (and 
perhaps are still being recruited) without the benefit of 
IRB oversight. 
 
The last sentence has a reference to the CARES website about Dr. New’s 
research, which we addressed earlier. 
 
Two claims are made in this paragraph of the LoC. The first is that off-label 
use of prenatal dexamethasone “appears to constitute a de facto clinical trial.” The 
second is that Dr. New is conducting follow-up studies of the long-term outcomes of 
prenatal dexamethasone without IRB approval. The latter claim is demonstrably false, 
as is clear from the plain language in Dr. New’s 2001 report on the follow-up, which 
states: “The study was approved by our institution’s review board for human rights in 
research. Informed consent was obtained from mothers” (New et al. 2001, 5654; see 
also Trautman et al. 1995, which is cited in the LoC). 
 
The claim that prenatal use of dexamethasone is a “defacto clinical trial” is 
neither clarified nor justified by the LoC. Assertion made without supporting 
argument, as Plato had Socrates teach us long ago, constitutes “mere opinion.” “Mere 
opinions” are not valid argument forms, because they are conclusions in search of 
premises. 
 
To determine whether supporting premises might be available, we performed a 
literature search in PUBMED using “off label use AND ethics” that yielded 68 
citations (April 22, 2010). The oldest citation is from 1994. The absence of a literature 
on the topic means that there was no ethical analysis and argument, much less a 
consensus ethical standard, that off-label use of prescription medications is research. 
Thus, no ethical standard for off-label use of drugs existed when Dr. New began her 
treatment protocol in 1986. The LoC falsely assumes such a standard has always 
existed. To avoid this criticism, the  LoC could have cited a consensus ethical 
standard. The LoC does not do so 
because, as our review of the 68 citations indicates, there is no such standard in the 
literature. Grant, for the sake of argument, that such a standard has just been created. 
To apply it to clinical practice from 25 years ago commits the terror of presentism, i.e., 
applying ethical standards of the present as if they applied throughout human history, 
against which historians rightly warn us (Pernick 2009). The claim that prenatal 
administration of dexamethasone constitutes a “de facto clinical trial” fails. 
 
UNDOCUMENTED CLAIM THAT PREGNANT WOMEN MAY NOT HAVE 
PROVIDED INFORMED CONSENT FOR ADMINISTRATION OF 
DEXAMETHASONE 
 
The sixth paragraph of the LoC states:  
 
It does not appear that physicians prescribing this drug to 
hundreds of women have sought IRB approval for clinical 
trials of dexamethasone for the purposes of minimizing 
virilization [and that therefore] pregnant women who have 
been prescribed dexamethasone external to IRB-approved 
trials may not have provided fully informed consent as 
would happen formally under an IRB-approved trial. 
 
The LoC assumes that obstetricians prescribing dexamethasone in such cases 
would not adhere to ethical and legal standards of informed consent in clinical 
practice, simply because there was no IRB oversight. This is a non sequitur. Moreover, 
it calls into question the professional integrity of scores of physicians without a shred 
of evidence being offered for the plausibility of the hypothesis of systematic and 
widespread violation of the ethical and legal standards of informed consent in obstetric 
practice for the prenatal administration of dexamethasone. 
 
A CALL FOR CLINICAL TRIALS: AN UNORIGINAL CLAIM THAT LACKS 
SUPPORTING ARGUMENT 
 
The LoC states in its seventh paragraph: 
 
Given the well-established risks to fetal development, 
physicians should initiate treatment of this type only 
through structured clinical trials with human subjects 
research protections in place. 
 
This call for clinical trials under IRB oversight is not based on the earlier claim 
that off-label use of prenatal dexamethasone is by definition experimental, which we 
addressed earlier. It is, instead, the claim that, because the long-term outcomes of 
prenatal administration dexamethasone are not known and because some risks have 
been reported, prenatal dexamethasone should be offered only under a clinical 
protocol. To be sure, the authors of the LoC trade heavily on the existence of 
uncertainty as regards the risks of dexamethasone, but the mere existence of 
disagreement does not speak to the merits of whether there is empiricalsupport for 
disagreement about the risks of dexamethasone.We have suggested that much of this 
uncertainty is predicated on studies that either are not germane to the specific question 
regarding the administration of dexamethasonein this setting or are predicated on 
small clinical studies that are statistically underpowered compared to the data reported 
by Dr. New and in which tentative observations of potential harm are not reproduced 
in subsequent studies. The authors may have gleaned their argument from Miller 
(1999) in his 1999 paper cited by the LoC, but the Miller paper is not cited in this part 
of the LoC. Perhaps this is becauseMiller offers nomore empirically substantive 
basisfor his claims than the authors of the LoC proffer. 
 
The LoC statement is not consistent with the 2002 consensus statement from 
the Lawson Wilkins Pediatric Endocrine Society and the European Society for 
Paediatric Endocrinology, which the LoC does not cite. This statement reads: “There 
is substantial difference of opinion concerning whether prenatal treatment of CAH is a 
research endeavor” (Joint LWPES/ESPE CAHWorking Group 2002, 4049). No 
position is taken on the matter, a fact that the LoC fails to report. 
 
In bioethics when one asserts a position that is controversial, one is obligated 
as a matter of intellectual integrity to advance an argument for one’s position (De 
Grazia and Beauchamp 2001). The LoC offers as the single premise: “Given the well 
established risks to fetal development.” As we pointed out earlier, in the absence of a 
structured scientific review of the literature and an analysis of the NNT and NNH 
based on such a review, the use of “well established” lacks empirical justification. 
Grant, however, that it is a reasonable claim. This “premise” reflects an incomplete 
ethical analysis, because there is no comprehensive analysis of the outcomes. For the 
premise to reflect an adequate ethical analysis, one would have to show that, on 
balance, the well established risks are not offset by clinical benefits, especially the 
amelioration of virilization. The consensus statement from the Joint LWPES/ESPE 
CAH Working Group states that it is “clear” that such ameliorization is accomplished, 
a conclusion that we believe is readily sustained by an assessment of the totality of the 
literature, including the body of clinical studies published by Dr. New. The claim that 
there should be clinical trials lacks supporting argument. 
 
CLINICAL TRIALS SHOULD NOT BE PURSUED: A CLAIM THAT 
CONTRADICTS THE CALL FOR CLINICAL RESEARCH 
 
In the final paragraph of the LoC, which comes immediately after the paragraph in 
which the call for clinical trials is made, the LoC states: 
 
Finally, we agree with Dr.Walter Miller, Distinguished 
Professor of Pediatrics and Chief of Endocrinology at the 
University of California San Francisco, who has written 
that “this experimental treatment is not warranted and 
should not be pursued even in prospective clinical trials.” 
 
The quoted passage is from a recent column by Miller in EndocrineNews 
(Speiser and Miller 2008). In it, he provides a condensed version of the argument that 
he made in his 1999 paper, cited in the LoC and discussed earlier. Miller concludes his 
EndocrineNews column with: “It is this author’s opinion that this experimental 
treatment is not warranted and should not be pursued, even in prospective clinical 
trials” (Speiser and Miller 2008, 17). Miller provides no argument for his opinion, 
which is required to justify the rejection of his earlier call for clinical trials (Miller 
1999). In endorsing Miller’s opinion that clinical trials should not be undertaken the 
LoC contradicts its call, issued in the preceding paragraph, for clinical trials to be 
undertaken. The LoC thus violates the law of noncontradiction, the most fundamental 
requirement of argument-based reasoning. 
 
MAJOR DIFFERENCES BETWEEN VERSION CIRCULATED TO SOLICIT 
CO-SIGNATORIES AND SUBMITTED VERSION 
 
The original version circulated to solicit individuals to become co-signatories 
contained no references. Major changes were made after co-signatories added their 
names to the draft LoC. There was no indication that changes would subsequently be 
made after the agreement of co-signatories to add their names. 
 
In an exchange on the bioethics listserv sponsored by the Medical College of 
Wisconsin, two of us (FAC and LBM) pointed out that numerous claims were made 
without substantiation in what turned out to be a draft version of the LoC. The initial 
response of the authors was that the LoC was not a scholarly paper and therefore was 
somehow exempt from accepted standards of scholarship. Such a position would 
disable transgressive bioethics. References were added in the submitted version. We 
addressed earlier the inadequacy, misuse, and false representation of the references. 
This substandard scholarship disables the LoC as transgressive bioethics that meets 
minimal standards of intellectual rigor and integrity. 
 
The opening sentence of the circulated unreferenced draft reads: “We write to 
express our grave concern that a research group affiliated with your institution may be 
engaging in an unapproved, off-label pharmaceutical trial targeted at pregnant women 
and their fetuses.” This sentence does not appear in the submitted version. The sixth 
paragraph of the submitted LoC concludes with: “Public descriptions of this drug as 
safe and effective may have misled some women to believe the use is FDA-approved, 
when it is not.” This sentence does not appear in the draft circulated to solicit co-
signatories. The final paragraph of this version of the LoC starts with: “We call for 
rigorous investigation by your institution into whether researchers associated with 
your institution are currently or have previously treated pregnant women with 
dexamethasone to prevent genital virilization.” The final paragraph of the submitted 
LoC begins with: “We call for rigorous investigation by the FDA into possible 
regulatory violations in this matter.” 
 
There is no indication in the submitted LoC that the cosignatories were made 
aware of these major changes in the LoC. There is also no indication that the co-
signatories read and approved the submitted version of the LoC. 
 
CONCLUSION 
 
Rebecca Dresser and Joel Frader (2009) recently called for “responsible self-
regulation” of off-label use of drugs. This has been a common practice not only in 
obstetrics but also in pediatrics and adult medicine and surgery in general for decades. 
Specifically, there is ongoing discussion in the scientific community on whether the 
prenatal administration of dexamethasone to prevent the complications of CAH in 
affected females is experimental or standard of care (Joint LWPES/ESPE CAH 
Working Group 2002). 
 
The LoC could have contributed to this important topic. Instead, the LoC 
makes false claims; misrepresents scientific publications and websites; fails to meet 
the fundamental standards of evidence-based reasoning; makes undocumented claims; 
treats as settled matters what are, instead, ongoing controversies; offers “mere 
opinion” as a substitute for argument; and makes contradictory claims. The LoC is 
therefore a case study in unethical transgressive bioethics. 
 
We call on fetaldex.org as the self-proclaimed organizer of “a group of 
professional researchers in bioethics and allied fields to file formal letters of concern” 
(fetaldex.org 2010b), and the corresponding author to withdraw the LoC from the 
government agencies and academic institutions to which it was submitted and to 
announce the withdrawal publicly on its website and the bioethics listerv. We also call 
on the co-signatories to remove their names from the LoC, to report their decision to 
remove their names to the government agencies and academic institutions to which the 
LoC was sent, and to inform fetaldex.org of their decision. We call on fetaldex.org to 
post notices of withdrawal by co-signatories from the LoC on its website.  
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APPENDIX: fetaldex.org LETTER OF CONCERN FROM BIOETHICISTS 
 
The following letter has been sent to: 
 
1. the FDA Office of Pediatric Therapeutics; 
2. the HHS Office for Human Research Protections; 
3. Mount Sinai Medical Center (Dr. New’s current institution); 
4. Weill Medical School of Cornell University (from which much of this treatment 
appears to have been administered, under Dr. New’s guidance); 
5. Florida International University (where Dr. New is Associate Dean for Clinical 
Research). 
 
The preliminary FDA response is shown here; the Office of Human Research 
Protections preliminary response is shown here. 
 
Dear Sir or Madam: 
We write to express our grave concern over possible non-IRB-approved 
clinical research on pregnant women that has been conducted under the auspices of 
Mount Sinai Medical Center and Weill Cornell Medical College, Cornell University, 
under the direction of Dr. Maria New. 
 This work involves off-label administration of dexamethasone to pregnant 
women who may give birth to girls with Congenital Adrenal Hyperplasia (CAH). It is 
our understanding that Dr. New has long prescribed dexamethasone for purposes of 
preventing genital virilization associated with CAH in 46,XX females. This indication 
is not approved by the FDA. Genital virilization is a cosmetic issue, one that has been 
recognized within Dr. New’s field as independent of the genuine medical concerns—
often serious and life-threatening in some forms of CAH—unaddressed by prenatal 
dexamethasone treatment. That is to say, prenatal treatment with dexamethasone is 
intended to avoid a cosmetic issue associated with CAH, rather than to treat the 
medical issues that should be the primary concern of physicians.[1] Furthermore, use 
of prenatal dexamethasone has been demonstrated to bear significant iatrogenic 
risk.[2] 
 
Off-label use of prescription medication is a long-time practice of medicine 
that has not been understood to constitute research requiring IRB oversight. We do not 
take issue here with the practice of off-label prescribing in general. We are concerned 
instead with a particular instance of what appears to constitute a de facto clinical trial 
involving many hundreds of patients now among the targeted “subjects” of long-term 
research. In clear violation of established bioethical protocols, these pregnant women 
appear to have been recruited (and perhaps are still being recruited) without the benefit 
of IRB oversight.[3] 
 
In professional contexts among her peers, Dr. New has publicly resisted 
discussion of the details of the information pregnant women and their partners are 
provided. One online promotion of the treatment with dexamethasone administered by 
Dr. New’s clinic nevertheless promised that follow-up with hundreds of children 
treated prenatally over 20 years “has found no adverse developmental consequences. . 
..the treatment appears to be safe for mother and child.”[4]  
 
Human studies have demonstrated, on the contrary, that prenatal 
dexamethasone treatment results in detrimental changes to the brains of children,[5] 
over 90% of whom will receive no benefit from this treatment. (Only 1 in 8 fetuses 
started on this treatment are actually 46,XX CAH, and of the 1/8 who are, 20% will 
not benefit from the treatment.) Children exposed prenatally to dexamethasone for 
CAH show problems with working memory, verbal processing, and anxiety.[6] 
Animal studies have also indicated reason to be very concerned about prenatal 
dexamethasone’s effect on fetal brains.[7] Therefore, contrary to the apparent claims 
aimed at prospective patients, dexamethasone treatment cannot responsibly be 
characterized as benign.[8] 
 
Despite knowledge of risks to fetal development, it does not appear that 
physicians prescribing this drug to hundreds of women have sought IRB approval for 
clinical trials of dexamethasone for the purposes of minimizing genital virilization in 
46,XX females at risk for CAH in utero. Pregnant women who have been prescribed 
dexamethasone external to IRB-approved trials may not have provided fully informed 
consent as would happen formally under an IRB approved trial. Public descriptions of 
this drug as safe and effective may have misled some women to believe the use is 
FDA-approved, when it is not. 
 
Given the well-established risks to fetal development, physicians should 
initiate treatment of this type only through structured clinical trials with human 
subjects research protections in place. Registered clinical trials ensure that women and 
their families make fully informed decisions with respect to the risks they assume for 
themselves and on behalf of their future children. Studies such as these also ensure 
that adverse effects will be noticed as soon as possible, and that any harm that comes 
to women and their children provide the benefit of increased scientific knowledge that 
can subsequently protect other women and babies from the same harms. 
 
We call for rigorous investigation into possible  regulatory violations in this 
matter. We also believe that women who have been treated without the protection of 
IRBs should now be advised of the information that may not have been made available 
to them at the time of treatment, and that they should be given the most recent 
information from studies indicating long-term risks to women and children. Finally, 
we agree with Dr. Walter Miller, Distinguished Professor of Pediatrics and Chief of 
Endocrinology at the University of California San Francisco, who has written that 
“this experimental treatment is not warranted and should not be pursued even in 
prospective clinical trials.”[9]  
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